Does CAPIVASERTIB Cause Malignant neoplasm progression? 62 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 62 reports of Malignant neoplasm progression have been filed in association with CAPIVASERTIB (TRUQAP). This represents 3.7% of all adverse event reports for CAPIVASERTIB.
62
Reports of Malignant neoplasm progression with CAPIVASERTIB
3.7%
of all CAPIVASERTIB reports
11
Deaths
13
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CAPIVASERTIB?
Of the 62 reports, 11 (17.7%) resulted in death, 13 (21.0%) required hospitalization, and 5 (8.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPIVASERTIB. However, 62 reports have been filed with the FAERS database.
What Other Side Effects Does CAPIVASERTIB Cause?
Diarrhoea (278)
Rash (253)
Death (228)
Hyperglycaemia (152)
Nausea (96)
Vomiting (81)
Blood glucose increased (70)
Fatigue (67)
Disease progression (61)
Pyrexia (55)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CAPIVASERTIB Alternatives Have Lower Malignant neoplasm progression Risk?
CAPIVASERTIB vs CAPLACIZUMAB
CAPIVASERTIB vs CAPLACIZUMAB-YHDP
CAPIVASERTIB vs CAPMATINIB
CAPIVASERTIB vs CAPREOMYCIN
CAPIVASERTIB vs CAPSAICIN